Foresite Capital Management IV’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Foresite Capital Management IV’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-450,000	Closed	-$2.39M	–	21
2018 Q1	$2.39M	Buy	+450,000	New	+$3.22M	0.99%	17

Other funds holding RARX

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Foresite Capital Management IV's RARX Position: Q2 2018 in Review

Foresite Capital Management IV sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2018, closing a stake of 450,000 shares — an estimated $2.39M sold.

Foresite Capital Management IV first reported a position in RARX in Q1 2018 and held it in 1 quarter. The position peaked at $2.39M in Q1 2018. 62 funds tracked by Wall St. Rank hold RARX as of Q2 2018.

Foresite Capital Management IV reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
Foresite Capital Management IV sold 450,000 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2018, an estimated $2.39M.
Foresite Capital Management IV first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q1 2018 and held it in 1 quarter.
Foresite Capital Management IV's Ra Pharmaceuticals, Inc. Common Stock position peaked at $2.39M in Q1 2018.
62 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2018.

Based on Foresite Capital Management IV's 13F filing for Q2 2018, filed 14 Aug 2018.